Seattle Genetics (SGEN) Initiates Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Hodgkin Lymphoma
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas.
The trial is designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients.
On August 19, 2011, the FDA granted accelerated approval of ADCETRIS for two indications.
The trial is designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients.
On August 19, 2011, the FDA granted accelerated approval of ADCETRIS for two indications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- Boeing names Ryan Shedd as new SVP and controller
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
